On April 11, 2018 Lytix Biopharma Reported that it will present data at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US (Press release, Lytix Biopharma, APR 11, 2018, View Source
[SID1234525270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Mikael J. Pittet, Associate Professor at Harvard Medical School, Senior Faculty of the Center for Systems Biology (CSB) at Massachusetts General Hospital (MGH) and Director of the CSB Cancer Immunology Program will present the data in a poster presentation from 8-12 am on Wednesday April 18. Previous experimental studies identified LTX-315’s ability to control cancer in mice grafted with various tumor cell lines triggering tumor-specific T cells. The analyses has now been extended to conditional genetic mouse models of both melanoma (driven by Braf and Pten alterations) and soft tissue sarcoma (driven by Kras and P53 alterations). In these genetic models, cancer cells are derived from somatic cells that are transformed in their normal tissue microenvironment and progress to high-grade tumors that are poorly infiltrated by T cells and typically resist prescribed chemo- and immunotherapeutic treatments.

"We are excited to present this data at AACR (Free AACR Whitepaper) in conjunction with Dr Pittet’s team which shows that LTX-315 not only delays tumor progression substantially in both models, but also profoundly alters the tumor microenvironment, most notably characterized with CD8+ T cell, NK cell and dendritic cell infiltration. A similar transition from a ‘cold’ to a ‘hot’ tumor microenvironment is seen in patients with melanoma, sarcoma and breast cancer after treatment with LTX-315. Furthermore, CD8+ T cell depletion in mice abrogated long-term antitumor efficacy of LTX-315, indicating that these cells are required for drug-induced tumor control. Importantly, the ability to convert non-T-cell-infiltrated tumors into ones that display antitumor T cell immunity opens the possibility to prime and make unresponsive tumors sensitive for systemic immune treatments," commented Dr Edwin Klumper, CEO of Lytix Biopharma.

View Source!/4562/presentation/8122

April 18, 2018, 8:00 AM – 12:00 PM
Section 25 Session PO.CL06.08 – Immunomodulatory Agents and Interventions 3

5549 / 5 – Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo- and immunotherapeutic treatments

M. J. Pittet1, H-W. Liao1, B. Sveinbjørnsson2, Ø. Rekdal2; 1Massachusetts Gen. Hosp., Boston, MA, 2Lytix Biopharma, Tromso, Norway

On April 11, 2018 ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, reported its presence at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) taking place April 14-18, 2018 in Chicago, USA (Press release, ADC Therapeutics, APR 11, 2018, View Source [SID1234525271]). Two poster presentations will highlight strong preclinical data for its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1. In addition, Dr. Jaewoong Lee, of The Beckman Institute of the City of Hope will make an oral presentation on novel preclinical data for ADCT-301 targeting CD25.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our two new investigational programs show compelling efficacy and safety in preclinical studies," said Dr. Jay Feingold, Chief Medical Officer and Senior Vice President of Clinical Development at ADCT. "These results provide an important step to advance ADCT-601 and ADCT-701 into the clinic and enlarge our pipeline of PBD-based ADCs in multiple ongoing clinical trials for the treatment of both solid and hematological cancers."

Poster titles and highlights of the data that will be presented are available on the AACR (Free AACR Whitepaper) conference website at www.aacr.org and include the following:

ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors Abstract #744, April 15, 1:00 pm – 5:00 pm CT

– ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK1, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199.

– ADCT-701 demonstrated potent and specific in vitro and in vivo anti-tumor activity in DLK1-expressing cancer-derived models and it was stable and well tolerated in rats.

Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors Abstract #2792A, April 16, 1:00 pm – 5:00 pm CT

– ADCT-601 is an ADC composed of a humanized IgG1 antibody against human AXL, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199.

– ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in various cancer-derived models with different levels of membranous AXL, and it was stable and well tolerated in rats.

CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Abstract #2983, April 16, 2018, 4:05 PM – 4:20 PM

– Novel data identifies CD25 as a previously unrecognized feedback regulator of oncogenic B/TCR-signaling supporting CD25 as a therapeutic target in refractory lymphoid malignancies.

– ADCT-301 demonstrated durable remissions in patient-derived Ph+ ALL cells PDX models

On April 11, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, reported that the company will present preclinical data related to PEN-866 at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, occurring April 14-18, 2018 in Chicago, IL (Press release, Tarveda Therapeutics,APR 11, 2018, View Source [SID1234525272]). PEN-866 is a miniature drug conjugate designed to treat patients with solid tumor types known to be sensitive to topoisomerase 1 inhibitors such as SN-38, the payload of PEN-866. The presentation will address the combination of PEN-866 with PARP inhibitors in models of ovarian cancer, lung cancer and colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy
Date:

April 18, 2018
Time:

8:00 AM – 12:00 PM CT
Location:

Section 37, McCormick Place North/South, Chicago, IL

About PEN-866
PEN-866 exploits the activation of Heat Shock Protein 90 (HSP90) in tumors to accumulate and release its potent anti-cancer payload, SN-38. PEN-866 is a miniature conjugate that comprises a small molecule, HSP90-targeting ligand linked to SN-38, the active metabolite of irinotecan. The conjugate accumulates and is retained in tumors, and by way of a sustained release of SN-38, causes prolonged DNA damage and tumor regressions in multiple patient-derived and other xenograft tumor models.

About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.

On April 11, 2018 Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, reported the publication of nonclinical results in Science Translational Medicine demonstrating the anti-cancer potential of ALRN-6924 in models of Acute Myeloid Leukemia (AML) (Press release, Aileron Therapeutics, APR 11, 2018, View Source;p=RssLanding&cat=news&id=2342163 [SID1234525472]). ALRN-6924 is designed to reactivate p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDM2 and MDMX. ALRN-6924 is being evaluated in Phase 1 and Phase 2 clinical trials in patients with AML, myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In AML, blood-forming stem cells in the bone marrow produce abnormal red and white blood cells as a result of damage to DNA. P53, a natural tumor suppressor, is inactive in AML, allowing cancer cells to grow unimpeded. Reactivating p53 with ALRN-6924 appears to slow or stop the growth of both mature and immature cancer cells. As demonstrated by the researchers at Albert Einstein in their nonclinical studies, treatment with ALRN-6924 increased the median survival rate in an animal model of human AML (mice transplanted with human leukemia cells) from 50 to about 150 days. In addition, about 40% of the animals were cured, meaning they were tumor-free at one year.

"These data further support our belief that p53’s function may be more effectively restored when both MDMX and MDM2 are blocked. ALRN-6924, a stapled peptide therapeutic shown to inhibit both protein targets, has the potential to deliver on the long-held promise that restoring apoptosis through the p53 pathway may be critical in treating certain cancers," said Manuel Aivado, M.D., Ph.D., Chief Medical and Scientific Officer of Aileron.

"This is a very striking response. Most experimental drugs for leukemia in our experience achieve an increase in survival of only a few days in these preclinical models. Even more importantly, ALRN-6924 effectively cured about 40 percent of the treated mice," said study leader Ulrich Steidl, M.D., Ph.D., Professor of the Departments of Cell Biology and of Medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Albert Einstein College of Medicine, and Associate Chair for Translational Research in Oncology at Montefiore.

The study in Science Translational Medicine is titled, "Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia."

About ALRN-6924
ALRN-6924 is a first-in-class product candidate designed to reactivate wild type p53 tumor suppression by disrupting the interactions between the two primary p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with p53. Based on preclinical data and preliminary evidence of safety and anti-tumor activity in its ongoing clinical trials, there may be a significant opportunity to develop ALRN-6924 as a monotherapy or combination therapy for a wide variety of solid and liquid tumors. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of acute myeloid leukemia (AML), advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL). For information about its clinical trials, please visit www.clinicaltrials.gov.

On April 11, 2018 Percans Oncology reported that it has developed i-CR, a personalized drug susceptibility testing platform for the precise treatment of colon cancer, to provide clinicians and patients with the most valuable medical plan for reference (Press release, Cothera Bioscience, APR 11, 2018, View Source [SID1234618854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Features of i-CR in vitro drug susceptibility testing platform

i-CR drug susceptibility testing technology focuses on the functionality of tumor cells. It investigates the response of tumor cells under the action of drugs instead of exploring the relationship between drug susceptibility and changes in genes and proteins. The i-CR results are more practical and correspondence to clinical outcomes. This technology takes small samples of patients’ tumors, and performs rapid and high-throughput, drug susceptibility tests for drugs that have been marketed or entered clinical trials, thus providing a strong basis for clinicians to make optmized medical plans for each individual patient.

Target Patients

l Patients newly diagnosed as stage III or IV colorectal cancer;

l Patients who have failed the standard first-line treatment plan and hope to choose the best plan;

l Patients who have local or distant metastases and cannot benefit from genetic testing;

l Patients who are resistant to targeted drugs and need to find effective multiple targeted drugs and targeted combinations.